Ticker | Value | Shares | Price | Security | Type | Insider | Title | Return | Flags | Date |
|---|---|---|---|---|---|---|---|---|---|---|
| No transactions found | ||||||||||
Matthew K. Fust currently holds 14,058 shares of Atara Biotherapeutics, Inc. (ATRA), valued at approximately $0. This represents their equity stake as Executive.
Based on SEC Form 4 filings, Matthew K. Fust has been a net seller of ATRA stock. They have purchased $205.6K and sold $14.8M worth of shares.
Matthew K. Fust's most recent insider trade was on May 14, 2026, when they sold 14,058 shares at $0.00 per share.
Matthew K. Fust serves as Executive at Atara Biotherapeutics, Inc. (ATRA). They have executed 144 insider transactions totaling $15.0M over their tenure at the company.
Matthew K. Fust holds the position of Executive at Atara Biotherapeutics, Inc., where they are responsible for executive-level decision-making and strategic oversight. They have been associated with the company for 19 years and currently hold a stake valued at $0.
Matthew K. Fust has shown a selling trading pattern, with $205.6K in total purchases and $14.8M in total sales across all transactions. Their most recent activity indicates a tendency to reduce their position.
The largest transaction by Matthew K. Fust was on Mar 20, 2024, when they sold $796.3K worth of CRNX shares. This transaction involved 17,500 shares at $45.50 per share.
Matthew K. Fust currently owns 14,058 shares of Atara Biotherapeutics, Inc. (ATRA), with an estimated value of $0. This stake represents their equity holdings accumulated through purchases, awards, and option exercises.
All of Matthew K. Fust's SEC Form 4 insider trading filings are tracked on this page. Each transaction links directly to the official SEC EDGAR filing. Matthew K. Fust has 144 Form 4 filings on record as an insider at Atara Biotherapeutics, Inc..
Set alerts for Matthew K. Fust and 40,000+ other insiders.